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Management of the Fontan 
circulation in the adult patient
univentricular heart is thankfully rare but the impact on survival 
is severe.
PRESENTATION OF UNIVENTRICULAR 
CIRCULATION
A univentricular heart will typically present in the neonatal period 
with variable cyanosis and failure to thrive. Increasingly, screening 
of the fetus in utero is allowing pre-natal diagnosis of a univentri-
cular heart. The management of prenatally diagnosed cases varies 
between healthcare systems and therefore the burden of patients 
with Fontan circulations on ACHD services will vary between 
countries and needs to be taken into consideration in planning 
ACHD service development
TYPES OF UNIVENTRICULAR HEART
There are many possible univentricular hearts and a number of 
classification schemes have been described. From an ACHD per-
spective it is useful to consider a few anatomical characteristics: 
atrial arrangement, atrioventricular valve morphology and ventri-
cular morphology (Figure 1a, 1b, 1c), as all of these features will 
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BACKGROUND
The Fontan circulation is a palliative surgical procedure first 
described nearly 40 years ago for the management of patients with 
a univentricular circulation. Over the years the operation has 
undergone a number of modifications from the one described by 
Francis Fontan, each leading to improvements in the patient’s 
wellbeing and survival. A child born today with a univentricular 
circulation in a country with a developed paediatric surgical pro-
gramme is likely to survive to adult life with relatively few problems. 
This paper will describe the concept of the univentricular circulation 
in detail, the operation described by Francis Fontan and its various 
subsequent modifications and how these patients are managed in 
adult life. There is little evidence base to the management of these 
patients and the various complex scenarios they face, and the views 
expressed here are based largely on the experience of managing 
these patients over many years in a specialised adult congenital 
heart disease (ACHD) unit. 
UNIVENTRICULAR HEART
The term “univentricular circulation” refers to a congenital heart 
defect in which a biventricular repair is not possible. This typically 
occurs in situations where there is hypoplasia of one of the 
ventricles, but can occur rarely in situations where two well-formed 
ventricles are present, but a biventricular repair is not possible due 
to other anatomical considerations. In all its various forms the 
The Fontan circulation poses challenges for the patient and 
clinician throughout the patient’s lifetime. Given the unique 
physiology of the Fontan circulation, even the best Fontan 
patient will have a degree of exercise limitation and, with 
advancing years, the life threatening complications of the 
condition become more common. Key to the preservation of 
life and minimising the effects of these complications is 
prompt recognition and management. Patients with this 
complex condition require lifelong follow up in specialised 
units, where all members of the multidisciplinary team are 
experienced in managing the patients. The provision of this 
level of care requires planning, and in all healthcare systems 
where these patients are, care should be taken to develop a 
system of adult congenital heart disease units to facilitate 
the management of these and other complex cardiac con-
ditions. This review summarises the anatomy and physiology 
of the Fontan circulation and provides guidance on the follow 
up of these patients and the complications they present with. 
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601
Sp
rin
g 
20
13
Vo
lu
m
e 
10
 •
 N
um
be
r 4
contribute to problems that may be faced in adult life, as will be 
discussed later. 
VENTRICULAR MORPHOLOGY AND OUTCOME
Whilst the perception is that a single morphological left ventricle 
will have a better prognosis than a single right ventricle, other 
anatomical considerations play a greater role in the long term 
outcomes of patients with a univentricular circulation. The approach 
to Fontan palliation for patients with tricuspid atresia or double 
inlet right or left ventricle is largely similar with a staged approach 
culminating in a total cavopulmonary connection. However isomeric 
hearts will have abnormalities of pulmonary and systemic venous 
returns that require special consideration. Similarly the hypoplastic 
left ventricle will require complex immediate palliation in the 
neonatal period which is associated with a high early mortality. 
These factors pass into adult life and palliated patients with isomeric 
circulations and hypoplastic left heart syndrome will have greater 
degrees of effort intolerance, a greater arrhythmia burden and will 
be more difficult to manage owing to the complexities of their 
condition.
SURVIVAL BEFORE FONTAN PALLIATION
The case for the Fontan circulation is easily made when considering 
survival statistics for patients with a univentricular circulation. The 
vast majority of patients with an unpalliated single left ventricular 
circulation will die before reaching adult life and survival is even 
worse with a single right ventricular circulation with survival above 
5 years unlikely and worse still with the hypoplastic left heart 
syndrome (HLHS) where unoperated survival beyond one week is 
rare. Therefore the case for surgery to improve survival is easily 
made, and the Fontan operation in its various forms does deliver 
survival benefit, with survival to adult life to be expected in even the 
most complex forms of a univentricular heart. However, the Fontan 
circulation comes at a cost, with significant morbidity in childhood 
and increasing into adult life. There are also limitations to cardio-
pulmonary performance which are inherent in the Fontan circulation 
and will be discussed in detail below. 
FONTAN ORIGINAL PAPER
In 1971, Francis Fontan published the first surgical paper outlining a 
palliative surgical procedure for patients with tricuspid atresia.(1) 
The paper describes in detail the formation of a valved conduit 
placed between the right atrium and the main pulmonary artery 
(MPA) with the formation of a classical Glenn connection between 
the superior vena cava (SVC) and the right pulmonary artery (RPA). 
It became apparent early on that the valved conduit placed an 
unacceptably high resistance to pulmonary blood flow and this pro-
A B C
FIGURE 1: Anatomical variations on a univentricular circulation.
A: Double inlet left ventricle with VA discordance and no pulmonary stenosis. 
B: Tricuspid atresia with hypoplastic RV, VA concordance and hypoplastic pulmonary artery. 
C: Hypoplastic left heart syndrome with AV and VA concordance, hypoplastic left ventricle, aorta and aortic arch. 
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cedure was altered to allow a direct connection of the right atrium 
to the main pulmonary artery, initially in combination with a classical 
Glenn operation, subsequently the connection was widened to 
allow flow into both pulmonary arteries and the SVC remained 
connected to the RA. This operation became the standard Fontan 
operation for many years and is referred to as a modified Fontan or 
an atriopulmonary (AP) Fontan operation.(2)
FONTAN’S TEN COMMANDMENTS
Follow up of Fontan’s early series of cases, allowed the team to 
establish key selection criteria that would predict a favourable 
outcome from surgery which have been refined to be age above 
four years, normal ventricular function, adequate pulmonary artery 
size, no distortion of pulmonary arteries from prior shunt surgery, 
low pulmonary artery pressure (below 15mmHg), low pulmonary 
vascular resistance, normal systemic venous drainage, no atrio-
ventricular valve leak, normal heart rhythm and no right atrial 
enlargement.(3) Follow up of patients meeting these criteria by 
Fontan’s group demonstrated an early mortality during the 6 
months following surgery that stabilised with good early survival but 
a steady decline from 6 years following surgery onwards. Survival 
rates being 92%, 89%, 88%, 86%, 81%, and 73% at 1 month, 
6 months, and 1, 5, 10, and 15 years following surgery.(4) Follow 
up of our own series showed improved survival of 90 %, 86 % and 
82 % at 5, 10 and 15 years, with multivariate analysis showing that 
pre-operative impaired ventricular function, elevated pulmonary 
artery pressures and early year of operation were the only pre-
dictors of early and late mortality following Fontan surgery whilst 
right atrial isomerism and small pulmonary arteries were predictors 
of reintervention.(5) Ventricular morphology did not predict early or 
late mortality in our series, however predictors of very long term 
survival (>20 years) remain to be established. This has lead our unit 
to consider ventricular function and pre-Fontan pulmonary artery 
pressures as the key points to consider whether Fontan palliation is 
a viable option. 
MODIFICATIONS TO THE FONTAN CIRCULATION
Whilst the AP Fontan was successful in providing long term survival 
and reduction in cyanosis, it is an inherently an inefficient circulation. 
The RA dilates with time and becomes a capacitance chamber into 
which the SVC and IVC flow return, the forward flow into the lungs 
becomes turbulent and of low velocity and becomes more 
dependent with time on inspiration and diastolic relaxation of the 
ventricle for transpulmonary blood flow. This is due to the reducing 
effect of atrial contraction as the RA dilates. 
The fundamentals of fluid mechanics need to be understood at this 
point: in a closed circuit turbulent flow leads to energy loss and an 
increase in power requirements. As the RA dilates with age the 
circulation becomes more inefficient and this places a greater stress 
on the single ventricle. Furthermore, in normal biventricular cir-
culations, the pulmonary and systemic circulations are synchro-
nised and each have a pump to work against the resistances. In the 
palliated univentricular circulation, the systemic circulation is pul-
satile and the pulmonary circulation is not, the circulations run in 
series and the non-pulsatile pulmonary circulation causes a large 
reflective wave of resistance leading to an increased afterload.(6)  In 
order to overcome this afterload the single ventricle hypertrophies. 
The hypertrophied ventricle requires an increased pre-load to 
maintain the cardiac output and yet the Fontan patient has no 
means of increasing trans-pulmonary blood flow, beyond a modest 
increase in heart rate and an increase in respiratory rate. 
DEVELOPMENT OF THE TOTAL 
CAVOPULMONARY CONNECTION (TCPC)
In order to address the issues of inefficiency in the Fontan circuit, 
Marc de Leval and colleagues developed the concept of a total 
cavopulmonary connection.(7) Using computational mathematical 
modeling techniques they demonstrated that by surgical creation 
of a tube to connect the IVC directly to the PA and by using a 
bidirectional Glenn, they could reduce power losses in the circuit 
and eventually by angling the connection of the IVC tunnel away 
from the SVC flow into the PA they optimised efficiency and 
minimised power losses. This tunnel can be achieved by two 
methods, which are routinely used in congenital surgical practice 
today: the lateral tunnel, created by the septation of the right atrium 
by means of a GoreTex patch(8) or by an extracardiac GoreTex 
tube, connecting the IVC to the PA.(9) This type of Fontan is 
often referred to as a “total cavopulmonary connection” or TCPC- 
Fontan (Figure 2). As previously discussed, this has the benefit of 
maximising trans-pulmonary blood flow, maintaining efficient 
laminar blood flow through the circuit, reducing the overall systemic 
vascular resistance which ameliorates ventricular hypertrophy, 
increasing transpulmonary blood flow and therefore recruits 
preload to the single ventricle. This improves resting and exercise 
haemodynamics. In patients in whom there may be concerns about 
post operative haemodynamics, a fenestration in the lateral tunnel 
or conduit can be made into the pulmonary venous atrial 
compartment, which will augment pre-load at the cost of mild 
cyanosis.(10)
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In 1981 Bill Norwood published the outcomes of his initial 
operations for palliation of the hypoplastic left heart syndrome 
(HLHS).(11) This condition is associated with almost universal 
mortality in the neonatal period, and Norwood utilised the 
formation of a side by side anastomosis of the main pulmonary 
artery and the hypoplastic aorta, with arch reconstruction, the so 
called Damus-Kaye-Stansel connection to create a unified outflow 
from the right ventricle.(12) This allows for completion of a Fontan 
palliation using a 3 stage approach (Figure 3).
  
For a full review of the management of the HLHS and the outcomes 
of the Norwood procedure and the hybird approach to the stage 
1 procedure (Figure 4) see our groups review.(13)
Our understanding of the specific physiological considerations of 
the Fontan circulation in the context of HLHS remains poor, 
however, the formation of a reconstructed ascending aorta and 
arch and the effects of this on aortic compliance and systemic 
vascular resistance remain a concern. How the RV will cope in this 
particular circulation remains to be established in the long run and 
concerns remain regarding coronary blood flow off the hypoplastic 
ascending aorta. All of these factors are likely to be detrimental to 
the long term systemic right ventricular function, in addition to the 
adverse haemodynamics of the Fontan circulation. 
HAEMODYNAMIC CONSEQUENCES OF FONTAN 
CIRCULATION 
The Fontan circulation in all its forms raises a challenge to our 
fundamental understanding of the circulation. Marc de Leval, dis-
cusses this at length in his review of 2005.(14) In short, the Fontan 
circulation is an alternative physiology to that described by Harvey 
and the long term management of the Fontan patient is dependent 
on a full understanding of this physiology. The cardiac output is 
dependent on adequate pre-load of the single ventricle, which in 
itself is dependent on a low pulmonary vascular resistance, mainte-
nance of sinus rhythm and systemic venous hypertension. This is 
demonstrated in Figure 5, where pressure in the various stages of 
the circulation is shown in the resting state and on exercise in a 
normal subject and in a Fontan patient.(15)  In a normal subject 
cardiac output is increased by pre-load recruitment with the effect 
of the muscular venous pump, being to increase RV pre-load, and 
increased heart rate and force of contraction pushing blood through 
the pulmonary vascular bed, leading to increased pre-load to the 
left ventricle and a consequent increase in stroke volume, which 
coupled with increased heart rate leads to an increase in cardiac 
output. In comparison, the lack of a sub-pulmonary pump and pre-
existent systemic venous hypertension, a requirement of the Fontan 
circulation, means that during exercise there is little pre-load 
A B C
FIGURE 2: The Fontan operation and its modifi cations.
A: Modified atriopulmonary Fontan with direct connection between the right atrium and pulmonary artery. 
B:  Lateral Tunnel Fontan, a type of total cavopulmonary connection Fontan, with septation of the atrium by a GoreTex patch to connect the IVC to 
the PA with a bidirectional Glenn. 
C: An extracardiac Fontan, a type of total cavopulmonary connection Fontan, with a GoreTex tube connecting the IVC to the PA. 
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recruitment and increases in cardiac output are determined by 
heart rate, but within a narrow range, as diastolic filling time 
becomes increasingly important to maintenance of pre-load . Thus, 
the Fontan patient is unable to increase cardiac output to the 
extent that a biventricular circulation can (Figure 5).(16) There is 
therefore a built in limitation and fragility to the Fontan physiology, 
which becomes important when considering the late complications 
that patients may face.
EXERCISE LIMITATION
Objective cardiopulmonary exercise testing is limited in the Fontan 
patient, when even the “asymptomatic” Fontan patient will have a 
reduction in the measured peak VO2, typically in our experience 
around 70% of the predicted value and this is consistent across the 
different ventricular morphologies and anatomies, except the HLHS 
patients who on average have a lower peak VO2 (62% of predicted). 
Further studies in adult Fontan patients are required to determine 
which groups, if any, have an adverse outcome with regards to 
exercise performance. 
 
FOLLOW UP OF ADULT FONTAN PATIENTS
Our standard approach to managing any adult with complex con-
genital heart disease starts in the teenage years, through the process 
A B C
FIGURE 3: The staged palliation of hypoplastic left heart syndrome (HLHS).
A:  Norwood stage 1. Formation of the Damus-Kaye-Stansel (DKS), anastomosis of the ascending aorta and main pulmonary artery creating a  
single outflow. Maintenance of pulmonary blood flow via a modified Blalock-Taussig shunt (MBTS). Aortic arch reconstruction. 
B: Norwood stage 2. Formation of a bidirectional Glenn (SVC to PA) and takedown of MBTS. 
C: Norwood stage 3. Completion of TCPC Fontan with extracardiac conduit. 
FIGURE 4: Hybrid approach to Norwood stage 1.  Maintenance of 
aortic fl ow by stenting of the arterial duct and limitation of pul-
monary blood fl ow by surgical application of bilateral PA bands.
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of transition. There is no absolute age at which transitional care 
starts, it clearly depends on individual patients’ circumstances, 
although we aim to have started the process by the age of 14 if 
possible. Our approach is for a specialist transitional care nurse 
to meet with the patient and family in the paediatric clinic and start 
to develop a relationship. We discuss the diagnosis and the 
operations they have undergone and what impact, if any, this has 
had on them as individuals. We start the discussion regarding 
pregnancy and contraception whilst also counseling the patient 
against the use of recreational drugs and cigarette smoking. We 
discuss alcohol consumption and other lifestyle issues such as 
piercing and tattoos and the need for regular dental follow up. This 
is a process that occurs over a number of clinic visits and culmi-
nates in their transfer to adult services between the ages of 16 
and 18 years. 
Advice is also given regarding career options. Currently the UK 
armed forces will not accept recruits with any history of congenital 
heart disease. We also discuss appropriate sporting and other 
leisure activities, including whether they can scuba dive.
At their first visit we cover the same points raised in transition 
clinics, perform a routine cardiovascular examination and the 
following routine examinations: 12 Lead ECG, transthoracic echo-
cardiogram, 24 hour ECG monitoring, cardiopulmonary exercise 
and cardiac MRI imaging in those in whom it is possible. This 
provides us with our baseline haemodynamic assessment, which we 
will compare future results with.
It is our standard practice to provide patients with a laminated copy 
of their 12 ECG for them to have with them in case they are ever 
reviewed in an emergency department with palpitations. Patients 
are also copied in to all correspondence so they have their own 
health care records. All patients are given contact details for the 
unit, the hospital and our clinical nurse specialists. Follow up is every 
12 months or at short notice if a situation arises.
Medications
The non-pulsatile and often turbulent blood flow through the 
Fontan, predisposes the patient to thromboembolism,(17)  which can 
have dire consequences. Even micro thrombi in the Fontan path-
way can, in time, lead to an increase in the pulmonary vascular 
resistance and large thrombi can occlude the circuit with fatal 
consequences.(18,19) In addition many patients have a right to left 
shunt and the risk of a paradoxical embolus is present. For these 
reasons we routinely anticoagulate our patients with Warfarin 
with a target INR of 2 to 2.5. Many centres advocate aspirin 
alone(20,21)  and although no reports demonstrate superiority,(22) it 
is clear that either is necessary and without antiplatelet or anti-
coagulant therapy thromboembolic events are frequent.(23)
FIGURE 5: Haemodynamic response to exercise in normal subjects (a) and Fontan patients (b), [Adapted from La Gerche and Gewillig. Int J Paediatr 
2010;2010. pii 791291. doi: 10.1155/2010/791291. Epub 2010 Sept 7.(15)] In the normal circulation exercise leads to a rise in aortic pressure and a 
modest rise in systemic venous pressure (S), RV pressure increases as does PA pressure leading to an increase in pulmonary venous pressure (P) and 
an increase in pre-load to the LV. In the Fontan circulation S is already high and must remain higher than P to allow transpulmonary blood fl ow and 
the result is that on exercise there is little if any augmentation of ventricular preload. 
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LV = left ventricle. Ao = aorta. RA = right atrium. RV = right ventricle. PA = pulmonary artery. LA = left atrium. CPB = cavopulmonary bypass.
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Many of our patients are transitioned on ACE inhibitors and whilst 
there is little evidence base to support their use,(24,25) we feel that 
there is no need to stop ACE inhibition and this is continued, 
often with a dose adjustment to adult dosage. 
Imaging modalities used in adult congenital heart patients
Transthoracic echocardiography (TTE) is our routine imaging 
modality. We have an experienced group of technicians who 
understand the anatomy of the various defects and the surgically 
altered hearts. This knowledge is built up over time and requires an 
ongoing process of professional development.
Echocardiography is excellent at imaging ventricular function, out-
flow tract obstruction and atrioventricular valve structure and 
function. It is not easy or often possible to assess Fontan pathway 
flow, obstruction and pulmonary venous pathway obstruction by 
TTE, so we also routinely use cardiac MRI to examine the Fontan 
pathway flow, to exclude obstruction and to look at the pulmonary 
venous return plus the other extra cardiac structures.
 
Transoesophageal echocardiography (TOE) in experienced hands 
can yield much of the information that TTE cannot. The pulmonary 
venous return is easily identified as is any thrombus within the 
Fontan circuit and clear views of the atrioventricular valves are 
obtained. Whilst we try to perform these cases under light sedation, 
many of the patients may require a general anaesthetic (GA).
Cardiac MRI for the Fontan circulation requires experienced tech-
nical support and radiologist or imaging cardiologist support. It 
provides single ventricle functional data, can look at Fontan path-
way flow,(26,27) exclude obstruction and look at pulmonary venous 
return.(28,29) In the HLHS post Norwood, it is the modality of choice 
for examining the Damus connection and the reconstructed aortic 
arch. It is time consuming and patients often find the magnetic 
claustrophobic and therefore cardiac MRI is not possible for all. It 
is also not possible to image patients with permanent pacemakers 
in the magnet. We have recently used gated cardiac CT in some 
individuals although our experience in this modality is insufficient to 
allow its true role to be established.
Cardiac catheterisation is used less in adults than in children, and 
again often requires a GA. However it does yield a wealth of 
information, both functional and pressure data and indirect 
estimates of cardiac output by measurement of the mixed venous 
saturation. Great care must be taken to ensure accurate zeroing 
of the pressure tracings as gradients as little as 1-2mmHg may be 
significant in these patients. We also use cardiac catheterisation 
to guide our interventions, often with TOE guidance. In adults 
catheter based interventions are not common, but may include 
stenting of branch pulmonary artery stenosis or venous pathway 
obstruction.(30) Coil or vascular plug embolisation of collaterals 
may be necessary in the profoundly cyanosed and also in patients 
with aortobronchial fistula, presenting with haemoptysis.(31-33)
Assessment of exercise performance
Exercise testing is carried out at transition for nearly all ACHD 
patients. Whilst we previously used a standard Bruce protocol, this 
has proven to be a poor tool for discriminating who is limited. We 
now use cardiopulmonary exercise testing as a routine and the 
ability to demonstrate when a maximal test has been performed 
is key. The test will discriminate between respiratory, cardiac or 
neuromuscular causes of exercise limitation and can be used to 
guide the timing of and assessing the efficacy of an intervention. 
We prefer to use in the able bodied a RAMP protocol on a stand-
ard treadmill, with continuous assessment of gas exchange. We 
routinely record the peak oxygen consumption (pVO2), the respi-
ratory exchange ratio (RER), the oxygen pulse, the anaerobic 
threshold (AT) and the VE/VCO2 slope. These can then be tracked 
in subsequent tests to assess for deterioration.
Typically a Fontan patient will manage a pVO2 around 60-70% of 
predicted values,(24) indicating a severe level of limitation and yet 
many may express little if any limitations to activities. Whilst the 
reasons for this are complex, Fontan patients in childhood are often 
advised to limit their activities and yet there is evidence for the 
benefits of exercise for Fontan patients.(35,36) 
Holter monitoring
Whilst many would advocate routine ambulatory ECG monitoring 
for all Fontan patients, we are guided by symptoms and in the 
asymptomatic patient we would not routinely do this. However we 
do pursue the cause of palpitations in those who report symptoms 
and would advocate ambulatory ECG monitoring, event recorders 
and in some reveal devices. It is ideal to be able to demonstrate 
what the clinically relevant arrhythmia is to our electrophysiology 
colleagues, so that they can plan ablation procedures. Whether 
routine electrophysiology studies will be a standard of care for 
these patients remains uncertain.
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Pregnancy and contraception
A number of centres have reported the outcomes of pregnancies 
in women with a Fontan circulation.(37-39) In general both fetal and 
maternal outcomes in pregnancies carried to term are good, how-
ever there is a high risk of fetal loss in the first two trimesters and 
an increased risk of prematurity. Careful pre-pregnancy assessment 
and counseling is warranted and we provide this through a 
dedicated combined obstetric cardiology clinic and patients are 
monitored throughout their pregnancy. Specific issues encountered 
are the need to convert warfarin to low molecular weight heparin 
for the duration for the pregnancy, with the need for weekly anti-
Xa monitoring. Patients on an ACE inhibitor need to stop this for 
the duration of the pregnancy. The delivery plan is discussed with 
the obstetrician, anaesthetist and cardiologist, generally we prefer a 
normal vaginal delivery at term with a short second stage. Caesarian 
sections are not mandated and may lead to haemodynamic 
instability and require careful fluid management.
Following pregnancy we aim to repeat the baseline imaging and 
exercise testing around 6 months postpartum to assess what, if 
any, effects the pregnancy may have had on cardiac function and 
performance.
Contraception councelling for Fontan patients is important. 
Oestrogen containing contraception is not recommended as this 
may increase the risk of venous thromboembolism. We advocate 
progestogen only contraception in the form of Cerazette, 
Nexplanon or Depo-provera. The Mirena coil is effective and safe 
for those who have undergone a pregnancy, but is not advisable 
in those who are nulliparous. Barrier methods are cardiac safe but 
are not as effective.
LONG TERM COMPLICATIONS OF THE FONTAN 
CIRCULATION
Atrial Arrhythmias
A frequent and life threatening complication is the occurrence of 
sustained atrial arrhythmias.(40,41) The prompt recognition of the 
abnormal rhythm allows for rapid management of the arrhythmia 
which can be life saving. Our experience is that we are often called 
by an emergency room physician who is seeing a Fontan patient 
who reports an arrhythmia but who is in a normal rhythm. 
Typically the arrhythmia takes the form of a macro re-entry scar 
related tachycardia. Due to the extent of scarring in the atrial mass, 
the cycle length of the arrhythmia is typically long leading to a 
modest tachycardia of around 110-130 bpm. The ECGs below 
(Figures 6a, 6b, 6c) are taken from the same patient. They represent 
two clinical arrhythmias and one is in sinus rhythm. They were all 
initially reported as normal. 
The consequences of a failure to act swiftly can be fatal. The 
tachycardia leads to a relative increase in the pulmonary venous 
atrial pressure, reducing the transpulmonary blood flow, reducing 
ventricular pre-load and cardiac output. The Fontan circuit is parti-
cularly susceptible to reductions in pre-load as discussed above, 
and patients may rapidly become compromised. Prompt action is 
required. The patient must be considered for synchronised DC 
cardioversion at the earliest opportunity. Whilst nil by mouth, they 
must be given intravenous fluids to support the systemic venous 
blood pressure that drives the transpulmonary blood flow. Fluids 
should be given where possible, by an air filtered line. Cardioversion 
under sedation is safe, but patients often prefer a GA. This should 
be performed by an experienced anaesthetist with slow intrave-
nous anaesthesia, bearing in mind the compromised circulation 
and the slow flow through the Fontan circulation. Care should be 
given not to drop the systemic vascular resistance as this may 
cause circulatory collapse, and we will have an alpha1-adrenergic 
receptor agonist, such as metaraminol available to support the 
systemic vascular resistance (SVR) if necessary. Rapid synchronised 
DC cardioversion is then performed, using 200j in a monophasic 
defibrillator and 150j in a biphasic defibrillator, a rapid sequence 
of shocks is appropriate if the initial shock does not restore sinus 
rhythm.
Following successful cardioversion in a Fontan patient or any 
other complex congenital heart lesion, our current strategy is to 
offer electrophysiology studies (EPS) with a view to performing 
radio-frequency ablation of the scar related flutter circuit. The 
advent of 3D mapping systems has aided the management of 
these complex arrhythmias.(42) Our standard medical therapy is 
beta-blockade with a cardio-selective agent, typically bisoprolol. 
Some advocate the use of sotalol owing to its additional class 3 
activity.(43)  We reserve amiodarone for recurrent atrial arrhythmias 
or sustained ventricular arrhythmias. The prolonged use of amio-
darone has a high risk of thyroid dysfunction(43,44) and photosensiti-
vity reactions can be a major problem.
Whether an elective EP study for all adult Fontan patients is justified 
remains to be determined, but this may be warranted, especially 
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FIGURE 6: 12 lead ECG taken from the same patient with a Fontan circulation.
A:  A macro-reentrant atrial tachyarrhythmia. Note the relatively long cycle length.
B:  A different macro-reentrant atrial tachyarrhythmia with a shorter cycle length.
C: Normal sinus rhythm.
A
B
C
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given the association of arrhythmias and mortality in these patients.
(45,46) There will be difficulties encountered in EPS in patients with an 
extra-cardiac conduit Fontan, as there is no direct connection 
between the venous system and the atrial mass, however there are 
potential strategies.(47)
Thromboembolism
The Fontan circuit by virtue of the low flow at rest and the lack of 
a sub-pulmonary ventricle is prone to thromboembolic pheno- 
mena. The abnormalities in clotting factors occur due to the Fontan 
circuit formation(48-50) and although the incidence of thrombo-
embolism is lower in TCPC Fontan patients,(21) it can nevertheless 
occur(51) and we advocate anticoagulation with warfarin for all 
Fontan patients regardless of type.
Thrombus may present with evidence of pathway obstruction, 
such as ascites and the onset of protein losing enteropathy asso-
ciated with effort tolerance and must be actively excluded. We 
use CT and MRI to look for patency of the Fontan pathway and 
the pulmonary arteries. Once demonstrated the management is 
difficult, routine anticoagulation with low molecular weight heparin 
and oral anticoagulation for those not routinely anticoagulated 
may be sufficient. Case reports have described successful outcomes 
with catheter delivered thrombolysis(52) and even surgical embo-
lectomy(53,54) and Fontan conversion surgery,(55,56) however, a large 
occlusive thrombus is frequently fatal, regardless of management 
strategy.(53,57) Figures 7 and 8 each show a large thrombus in the 
right atrium of an AP Fontan patient, with Tricuspid Atresia. Patient 
1 underwent a successful surgical removal and conversion to an 
extra-cardiac TCP Fontan, Patient 2, presented late with occlusion 
of his left pulmonary artery (LPA) and near total occlusion of 
his right atrium as can be seen on this black blood MRI image. He 
had a classical Glenn and died despite full anticoagulation.
Fontan pathway obstruction
Even a minor degree of Fontan pathway narrowing can lead to 
significant haemoydynamic compromise. This can occur at the site 
of the RA-PA connection in the AP Fontan or at the insertion 
point of the SVC, lateral tunnel or extracardiac conduit in the 
TCPC Fontan, at the site of insertion of a previous systemic to 
pulmonary arterial shunt, or typically post Norwood Stage 1 with 
narrowing of the LPA as it passes by the reconstructed Damus 
connection.(58,59) These narrowed parts of the Fontan circuit would 
typically be addressed in the catheter laboratory with balloon 
dilatation or stent implantation in the older child and adult.(30,60-62) 
Pulmonary venous pathway obstruction
One of the unwanted effects of the modified atriopulmonary 
Fontan operation was dilatation of the right atrium, such that the 
right sided pulmonary veins became compressed.(63) This leads to 
an increase in the pulmonary vascular resistance and is associated 
with Fontan failure and is an indication for Fontan conversion 
surgery(55,64) to a total cavopulmonary connection where com-
pression of the veins is less likely.
Sub-aortic obstruction
The presence sub-aortic stenosis in the univentricular heart used 
to present the surgeon with great difficulty and any operation 
FIGURE 7: Cardiac MRI scan showing a large thrombus within an 
atriopulmonary Fontan chamber.
FIGURE 8: Cardiac MRI showing near occlusion of the 
atriopulmonary Fontan chamber by thrombus.
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was associated with a high mortality(65) until the adaptation of 
the Norwood 1 operation for use in this particular anatomy.(66) 
Whilst the Damus operation has evolved as the treatment of 
choice for patients presenting with sub-aortic stenosis, there 
remains a small proportion of patients for whom this is a late 
complication following Fontan surgery.(67-70) Surgery remains the 
standard management for this complication and can take the form 
of a sub-aortic resection(71) or late formation of a Damus connec-
tion.(72,73) However, this comes at a cost of significant operative 
mortality.(71) High risk patients include those with univentricular 
hearts and transposition of the great vessels.(74,75) 
In our experience patients have presented with effort intolerance 
and anginal symptoms but also asymptomatic with a progressive 
severe sub-aortic muscular obstruction. It remains a risk in many of 
the patients who have undergone a Fontan operation, and should 
be looked for during routine TTE.
 
Systemic atrioventricular valve regurgitation (AVVR) 
The mechanism of AVVR in patients with a univentricular circula-
tion remains poorly understood. It occurs in the non-palliated 
univentricular circulation(76,77) and may be addressed at the time of 
Fontan completion.(78,79) The development of AVVR post Fontan 
surgery is associated with morbidity and mortality(80-82) and surgery 
to repair the regurgitant valve is also associated with significant early 
and late mortality(83) however, if successful also leads to improve-
ments in ventricular function.(84)
Ventricular Dysfunction
The single ventricle pre-Fontan surgery is a chronically volume 
loaded chamber which undergoes adverse geometric changes if left 
volume loaded.(85) The Fontan operation leads to early improve-
ments in ventricular function and hypertrophy.(86-88) By adult life 
the gains in ventricular function are largely lost with around a third 
of reported patients having moderate or severe ventricular func-
tion.(89) There are many plausible theories as to why late ventri-
cular function occurs, with increasing systemic vascular resistance, 
due to abnormal vascular tone,(90) endothelial dysfunction,(91-93) and 
the abnormal resistances encountered by the pulmonary and sys-
temic circulations running in series(6) all probably playing a part. The 
onset of significant valvular incompetence and the onset of atrial 
arrhythmias are both poorly tolerated.
Whilst there is a lack of evidence base for the use of conven-
tional heart failure treatment, nevertheless there is little else to 
offer. Spironolactone may improve endothelial function(93) and 
carvedilol appears to improve systemic ventricular function(94) in 
Fontan patients, yet the role of ACE inhibitors remains unproven(24) 
despite their routine use alongside empirical use of diuretics. 
Protein-losing enteropathy (PLE)
PLE is a devastating late complication of the Fontan operation.(95) 
It is associated with chronic protein loss from the gastrointes-
tinal tract(96) and the presence of elevated fecal alpha-1 antitrypsin 
levels in association with a low serum albumin and generalised 
oedema is characteristic.(97,98) The exact cause remains uncertain 
but chronic elevation of systemic venous pressures, lymphatic 
dysfunction,(99,100) ventricular dysfunction,(101,102) abnormal pulmo-
nary vascular compliance(103) and intestinal heparan loss(104) have 
all been implicated. Pathway obstruction must be actively looked 
for and treated(98,102,105) and there are reports of PLE resolution 
by conversion to a TCPC Fontan(64,106,107) and by cardiac trans-
plantation,(108,109) however, both are technically challenging even 
without the presence of PLE and are associated with significant 
procedural mortality.
Many possible therapies have been suggested and these are 
directed symptomatic relief with diuretics(110) and dietary modi-
fications,(111,112) reduction in intestinal protein loss with the use of 
steroids(113-116) and heparin(117-123) and improving the haemodyna-
mics as described above. 
Cyanosis
A degree of cyanosis is common in most adult Fontan patients, 
in many due to a fenestration made at the time of Fontan 
completion in order to maintain cardiac output in the early post 
operative period with an associated reduction in morbidity and 
mortality.(10,124) Later percutaneous closure of the fenestration is 
often performed if cyanosis is profound and may be complete 
occlusion(125-127) or partial.(128,129) Similarly, baffle leaks in the suture 
line of the fontan circuit, may lead to cyanosis which may be closed 
percutaneously.(130) Venous collaterals are also common and may 
be addressed in the catheter lab.(131,132) Extra cardiac causes can 
occur and in some patients a severe restrictive lung defect may also 
occur, further impairing gas exchange. 
Cyanosis is a multi-system disorder, typically the patient may have 
impaired clotting, with low platelet counts and abnormal clotting 
factors. They are at risk of acute renal injury and every effort must 
be made to keep the patient well hydrated and avoidance of 
nephrotoxic agents is advised. As with all cyanotic cardiac patients, 
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the resting right to left shunt places the patient at risk of systemic 
paradoxical emboli, and all intravenous fluids/injections should be 
given via filtered lines. Also if unexplained neurological symptoms 
develop, patients should undergo screening for a cerebral abscess, 
a rare but significant complication of cyanotic heart disease. 
Bradyarrhythmias
Whilst bradyarrhythmias are not typical post Fontan surgery, they 
are difficult to manage. Endovascular pacing of the single ventricle is 
often not possible without a “transeptal puncture” and a systemic 
ventricular pacing lead is not considered ideal due to the risk of 
thromboembolic complications. In those with pure sinus node 
dysfunction endovascular atrial pacing is a good option.(132,133) The 
majority of ventricular pacing is epicardial.(134,135) This requires at 
best a limited thorocotomy and may require full sternotomy and 
cardiopulmonary bypass, with the associated risks. In some patients 
access to the coronary sinus is possible via the Fontan circuit and in 
these “LV” leads have been placed with some success.(136-139) Lead 
failure is not uncommon and again this is difficult to manage.(134,140)
Many centres will place epicardial pacing leads if a patient is 
undergoing conversion from an atriopulmonary to a TCPC Fontan 
as the risk of bradyarrhythmias is higher following the arrhythmia 
surgery typically performed during this operation.(141,142)
Hepatocellular carcinoma
Chronic elevation of the hepatic venous pressure is thought to lead 
to chronic liver pathology and there are a number of reported 
cases of hepatocellular carcinoma occurring late after Fontan 
surgery.(143-145) Screening for hepatic adenomas by annual liver 
imaging and alpha-feto protein levels has been recommended and 
is a low cost way of identifying these cases early in their disease 
course.(146-148)
 
Prognosis
It is clear that the management of the univentricular circulation is a 
success story if considered in terms of survival benefit. Inevitable 
death in childhood has been turned into likely survival to adult life 
for the majority, yet it comes at a cost. The burden of impaired 
effort tolerance, the risk of arrhythmias and the likely decline into a 
low cardiac output state, whilst still a young adult, is considerable. 
We do not know what the long term prognosis is for these 
patients. In the largest and longest follow up series published, a 
third of patients had died following a mean follow up period of 
12 years. Yet the majority of these deaths were peri-operative and 
in survivors, 20 year survival rates were 82%.(19) It is possible that 
surgical modifications will lead to improvements in early and late 
survival but that remains unproven. However, the success of 
the Norwood palliation for HLHS will also impact on these sur-
vival figures.(149)
Survival for patients with an atriopulmonary Fontan may improve 
by conversion to a TCPC type Fontan.(150) The associated improve-
ment in fluid mechanics and reduction in arrhythmia burden are 
likely to lead to survival improvements, but the operation requires 
careful consideration.(151) In carefully selected patients, the operation 
is associated with a low operative mortality.(151,152)
Role of transplantation
The difficulties of cardiac transplantation in patients with congenital 
heart disease has already been discussed in this journal (Bowater 
2013) and its use in Fontan patients is well described.(153,154) 
Early mortality is high(155-157) but later survival for those trans-
planted for impaired ventricular function is good. PLE prior to 
transplantation is associated with a poor long term outcome.(158,159) 
With improving early survival from staged Fontan surgery, there 
will be an inevitable increase in adults with failing Fontan circula-
tions in whom transplantation will be considered. The prospect 
of a mechanical Fontan support device has been raised and a 
number of designs have undergone mathematical modeling(160,161) 
and animal studies.(162-164)
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